Jump to content

Martin Landray: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
No edit summary
Line 12: Line 12:
Landray serves as co-chief investigator of the [[RECOVERY Trial]] into treatment drugs for [[COVID-19]] (the largest such clinical trial in the world) alongside [[Peter Horby]].<ref>{{Cite web|title=ISRCTN - ISRCTN50189673: A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)|url=http://www.isrctn.com/ISRCTN50189673|access-date=2020-09-06|website=www.isrctn.com|language=en}}</ref><ref>{{cite web |title=Large-scale trial for coronavirus drugs launches in UK |url=https://www.clinicaltrialsarena.com/news/coronavirus-trial-uk-treatments/ |website=Clinical Trials Arena |accessdate=7 September 2020 |date=6 April 2020}}</ref><ref>{{cite web |title=Managing clinical trials during the pandemic — Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences |url=https://www.ndorms.ox.ac.uk/news/managing-clinical-trials-during-the-pandemic |website=www.ndorms.ox.ac.uk |accessdate=7 September 2020}}</ref> In June 2020, the trial discovered the first known life-saving COVID-19 drug, [[Dexamethasone]].<ref>{{Cite web|title=Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 {{!}} University of Oxford|url=https://www.ox.ac.uk/news/2020-06-16-low-cost-dexamethasone-reduces-death-one-third-hospitalised-patients-severe|access-date=2020-09-06|website=www.ox.ac.uk}}</ref><ref>{{Cite web|title=Prime Minister's statement on coronavirus (COVID-19): 16 June 2020|url=https://www.gov.uk/government/speeches/pm-statement-at-the-coronavirus-press-conference-16-june-2020|access-date=2020-09-06|website=GOV.UK|language=en}}</ref><ref>{{cite journal | vauthors = Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ | display-authors = 6 | title = Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report | journal = The New England Journal of Medicine | volume = 0 | date = July 2020 | pmid = 32678530 | pmc = 7383595 | doi = 10.1056/NEJMoa2021436 }}</ref> The trial also showed that [[Tocilizumab]] further reduces the risk of death for the sickest patients with COVID-19.<ref>{{cite journal |title=RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |pmid=33933206}}</ref> The trial found that a number of other treatments had no meaningful benefits for patients hospitalised with COVID-19, including [[Hydroxychloroquine]],<ref>{{cite journal |last1=Group |first1=The RECOVERY Collaborative |title=Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 |journal=New England Journal of Medicine |date=8 October 2020 |volume=383 |issue=21 |pages=2030–2040 |doi=10.1056/NEJMoa2022926 |pmid=33031652 |pmc=7556338 |url=https://www.nejm.org/doi/10.1056/NEJMoa2022926 |accessdate=16 October 2020 |language=en}}</ref> [[Lopinavir/ritonavir]],<ref>{{cite journal |last1=Horby |first1=Peter W. |last2=Mafham |first2=Marion |last3=Bell |first3=Jennifer L. |last4=Linsell |first4=Louise |last5=Staplin |first5=Natalie |last6=Emberson |first6=Jonathan |last7=Palfreeman |first7=Adrian |last8=Raw |first8=Jason |last9=Elmahi |first9=Einas |last10=Prudon |first10=Benjamin |last11=Green |first11=Christopher |last12=Carley |first12=Simon |last13=Chadwick |first13=David |last14=Davies |first14=Matthew |last15=Wise |first15=Matthew P. |last16=Baillie |first16=J. Kenneth |last17=Chappell |first17=Lucy C. |last18=Faust |first18=Saul N. |last19=Jaki |first19=Thomas |last20=Jefferey |first20=Katie |last21=Lim |first21=Wei Shen |last22=Montgomery |first22=Alan |last23=Rowan |first23=Kathryn |last24=Juszczak |first24=Edmund |last25=Haynes |first25=Richard |last26=Landray |first26=Martin J. |title=Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |journal=The Lancet |date=5 October 2020 |volume=0 |issue=10259 |pages=1345–1352 |doi=10.1016/S0140-6736(20)32013-4 |pmid=33031764 |pmc=7535623 |url=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32013-4/fulltext |accessdate=16 October 2020 |language=English |issn=0140-6736}}</ref> [[Azithromycin]],<ref>{{cite journal |title=Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |pmid=33545096}}</ref> [[Convalescent plasma]],<ref>{{cite journal |doi=10.1101/2021.03.09.21252736}}</ref><ref>{{cite journal |title=Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |doi=10.1101/2021.03.09.21252736}}</ref> and [[Colchicine]].<ref>[https://www.recoverytrial.net/news/recovery-trial-closes-recruitment-to-colchicine-treatment-for-patients-hospitalised-with-covid-19]</ref> The trial continues to study [[REGN-COV2]] and [[Baricitinib]].<ref>{{cite web |title=Welcome — RECOVERY Trial |url=https://www.recoverytrial.net/ |website=www.recoverytrial.net |accessdate=16 October 2020}}</ref>
Landray serves as co-chief investigator of the [[RECOVERY Trial]] into treatment drugs for [[COVID-19]] (the largest such clinical trial in the world) alongside [[Peter Horby]].<ref>{{Cite web|title=ISRCTN - ISRCTN50189673: A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)|url=http://www.isrctn.com/ISRCTN50189673|access-date=2020-09-06|website=www.isrctn.com|language=en}}</ref><ref>{{cite web |title=Large-scale trial for coronavirus drugs launches in UK |url=https://www.clinicaltrialsarena.com/news/coronavirus-trial-uk-treatments/ |website=Clinical Trials Arena |accessdate=7 September 2020 |date=6 April 2020}}</ref><ref>{{cite web |title=Managing clinical trials during the pandemic — Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences |url=https://www.ndorms.ox.ac.uk/news/managing-clinical-trials-during-the-pandemic |website=www.ndorms.ox.ac.uk |accessdate=7 September 2020}}</ref> In June 2020, the trial discovered the first known life-saving COVID-19 drug, [[Dexamethasone]].<ref>{{Cite web|title=Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 {{!}} University of Oxford|url=https://www.ox.ac.uk/news/2020-06-16-low-cost-dexamethasone-reduces-death-one-third-hospitalised-patients-severe|access-date=2020-09-06|website=www.ox.ac.uk}}</ref><ref>{{Cite web|title=Prime Minister's statement on coronavirus (COVID-19): 16 June 2020|url=https://www.gov.uk/government/speeches/pm-statement-at-the-coronavirus-press-conference-16-june-2020|access-date=2020-09-06|website=GOV.UK|language=en}}</ref><ref>{{cite journal | vauthors = Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ | display-authors = 6 | title = Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report | journal = The New England Journal of Medicine | volume = 0 | date = July 2020 | pmid = 32678530 | pmc = 7383595 | doi = 10.1056/NEJMoa2021436 }}</ref> The trial also showed that [[Tocilizumab]] further reduces the risk of death for the sickest patients with COVID-19.<ref>{{cite journal |title=RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |pmid=33933206}}</ref> The trial found that a number of other treatments had no meaningful benefits for patients hospitalised with COVID-19, including [[Hydroxychloroquine]],<ref>{{cite journal |last1=Group |first1=The RECOVERY Collaborative |title=Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 |journal=New England Journal of Medicine |date=8 October 2020 |volume=383 |issue=21 |pages=2030–2040 |doi=10.1056/NEJMoa2022926 |pmid=33031652 |pmc=7556338 |url=https://www.nejm.org/doi/10.1056/NEJMoa2022926 |accessdate=16 October 2020 |language=en}}</ref> [[Lopinavir/ritonavir]],<ref>{{cite journal |last1=Horby |first1=Peter W. |last2=Mafham |first2=Marion |last3=Bell |first3=Jennifer L. |last4=Linsell |first4=Louise |last5=Staplin |first5=Natalie |last6=Emberson |first6=Jonathan |last7=Palfreeman |first7=Adrian |last8=Raw |first8=Jason |last9=Elmahi |first9=Einas |last10=Prudon |first10=Benjamin |last11=Green |first11=Christopher |last12=Carley |first12=Simon |last13=Chadwick |first13=David |last14=Davies |first14=Matthew |last15=Wise |first15=Matthew P. |last16=Baillie |first16=J. Kenneth |last17=Chappell |first17=Lucy C. |last18=Faust |first18=Saul N. |last19=Jaki |first19=Thomas |last20=Jefferey |first20=Katie |last21=Lim |first21=Wei Shen |last22=Montgomery |first22=Alan |last23=Rowan |first23=Kathryn |last24=Juszczak |first24=Edmund |last25=Haynes |first25=Richard |last26=Landray |first26=Martin J. |title=Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |journal=The Lancet |date=5 October 2020 |volume=0 |issue=10259 |pages=1345–1352 |doi=10.1016/S0140-6736(20)32013-4 |pmid=33031764 |pmc=7535623 |url=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32013-4/fulltext |accessdate=16 October 2020 |language=English |issn=0140-6736}}</ref> [[Azithromycin]],<ref>{{cite journal |title=Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |pmid=33545096}}</ref> [[Convalescent plasma]],<ref>{{cite journal |doi=10.1101/2021.03.09.21252736}}</ref><ref>{{cite journal |title=Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |doi=10.1101/2021.03.09.21252736}}</ref> and [[Colchicine]].<ref>[https://www.recoverytrial.net/news/recovery-trial-closes-recruitment-to-colchicine-treatment-for-patients-hospitalised-with-covid-19]</ref> The trial continues to study [[REGN-COV2]] and [[Baricitinib]].<ref>{{cite web |title=Welcome — RECOVERY Trial |url=https://www.recoverytrial.net/ |website=www.recoverytrial.net |accessdate=16 October 2020}}</ref>


He has been one of the leaders of the Clinical Trial Transformation Initiative's<ref>[https://www.ctti-clinicaltrials.org/]</ref> risk-based monitoring,<ref>[https://www.ctti-clinicaltrials.org/sites/www.ctti-clinicaltrials.org/files/recommendations/monitoring-recommendations.pdf]</ref> quality-by-design,<ref>[https://www.ctti-clinicaltrials.org/projects/quality-design]</ref> and mobile clinical trial projects<ref>{{cite news |last1=Entis |first1=Laura |title=Can smartphone drug trials improve medical care? |url=https://www.theguardian.com/lifeandstyle/2016/jan/27/smartphone-mobile-drug-trials-fda-pfizer-ctti-depression-us-health |accessdate=16 October 2020 |work=The Guardian |date=27 January 2016}}</ref> and has driven work encourage the creation of new regulatory guidelines for clinical trials.<ref>{{cite journal |url=http://eurheartj.oxfordjournals.org/content/ehj/34/41/3161.full.pdf |accessdate=16 October 2020}}</ref>. He leads the Good Clinical Trial Collaborative, established by [[Wellcome Trust]], [[Bill & Melinda Gates Foundation]], and [[African Academy of Sciences]] which seeks to develop and promote the adoption of international guidelines for [[randomised control trial|randomised control trials]]. He is founding director and chair of NHS DigiTrials<ref>https://digital.nhs.uk/services/nhs-digitrials</ref>, the Health Data Research Hub for Clinical Trials hosted by [[NHS Digital]], and leads the clinical trials theme for Health Data Research UK.<ref>[https://www.hdruk.ac.uk/using-health-data/clinical-trials/]</ref>
He leads the Good Clinical Trial Collaborative, established by [[Wellcome Trust]], [[Bill & Melinda Gates Foundation]], and [[African Academy of Sciences]] which seeks to develop and promote the adoption of international guidelines for [[randomised control trial|randomised control trials]]. He was previously one of the leaders of the Clinical Trial Transformation Initiative's<ref>[https://www.ctti-clinicaltrials.org/]</ref> risk-based monitoring,<ref>[https://www.ctti-clinicaltrials.org/sites/www.ctti-clinicaltrials.org/files/recommendations/monitoring-recommendations.pdf]</ref> quality-by-design,<ref>[https://www.ctti-clinicaltrials.org/projects/quality-design]</ref> and mobile clinical trial projects<ref>{{cite news |last1=Entis |first1=Laura |title=Can smartphone drug trials improve medical care? |url=https://www.theguardian.com/lifeandstyle/2016/jan/27/smartphone-mobile-drug-trials-fda-pfizer-ctti-depression-us-health |accessdate=16 October 2020 |work=The Guardian |date=27 January 2016}}</ref> and has encouraged the creation of new regulatory guidelines for clinical trials.<ref>{{cite journal |url=http://eurheartj.oxfordjournals.org/content/ehj/34/41/3161.full.pdf |accessdate=16 October 2020}}</ref>. He is founding director and chair of NHS DigiTrials<ref>https://digital.nhs.uk/services/nhs-digitrials</ref>, the Health Data Research Hub for Clinical Trials hosted by [[NHS Digital]], and leads the clinical trials theme for Health Data Research UK.<ref>[https://www.hdruk.ac.uk/using-health-data/clinical-trials/]</ref>


In 2021, Landray was appointed to the Pandemic Preparedness Partnership (PPP), an expert group chaired by [[Patrick Vallance]] to advise the [[G7]] presidency held by the [[Government of the United Kingdom|government]] of [[Prime Minister of the United Kingdom|Prime Minister]] [[Boris Johnson]].<ref>[https://www.gov.uk/government/news/new-global-partnership-launched-to-fight-future-pandemics New global partnership launched to fight future pandemics ] [[Government of the United Kingdom]], press release of April 20, 2021.</ref>
In 2021, Landray was appointed to the Pandemic Preparedness Partnership (PPP), an expert group chaired by [[Patrick Vallance]] to advise the [[G7]] presidency held by the [[Government of the United Kingdom|government]] of [[Prime Minister of the United Kingdom|Prime Minister]] [[Boris Johnson]].<ref>[https://www.gov.uk/government/news/new-global-partnership-launched-to-fight-future-pandemics New global partnership launched to fight future pandemics ] [[Government of the United Kingdom]], press release of April 20, 2021.</ref>

Revision as of 10:49, 5 May 2021

Martin Landray
Alma materUniversity of Birmingham
Scientific career
InstitutionsUniversity of Oxford
Websitewww.bdi.ox.ac.uk/Team/martin-landray

Martin Landray is a British physician, epidemiologist and data scientist who serves as a Professor of Medicine & Epidemiology at the University of Oxford. Landray has specialist knowledge and experience at designing, conducting and analysing large-scale randomised control trials; including practice-changing international trials that have recruited over 100,000 individuals.[1] Landray previously led the health informatics team that enabled the collection and management of data for the UK Biobank on over half a million people.[2]

Landray serves as co-chief investigator of the RECOVERY Trial into treatment drugs for COVID-19 (the largest such clinical trial in the world) alongside Peter Horby.[3][4][5] In June 2020, the trial discovered the first known life-saving COVID-19 drug, Dexamethasone.[6][7][8] The trial also showed that Tocilizumab further reduces the risk of death for the sickest patients with COVID-19.[9] The trial found that a number of other treatments had no meaningful benefits for patients hospitalised with COVID-19, including Hydroxychloroquine,[10] Lopinavir/ritonavir,[11] Azithromycin,[12] Convalescent plasma,[13][14] and Colchicine.[15] The trial continues to study REGN-COV2 and Baricitinib.[16]

He leads the Good Clinical Trial Collaborative, established by Wellcome Trust, Bill & Melinda Gates Foundation, and African Academy of Sciences which seeks to develop and promote the adoption of international guidelines for randomised control trials. He was previously one of the leaders of the Clinical Trial Transformation Initiative's[17] risk-based monitoring,[18] quality-by-design,[19] and mobile clinical trial projects[20] and has encouraged the creation of new regulatory guidelines for clinical trials.[21]. He is founding director and chair of NHS DigiTrials[22], the Health Data Research Hub for Clinical Trials hosted by NHS Digital, and leads the clinical trials theme for Health Data Research UK.[23]

In 2021, Landray was appointed to the Pandemic Preparedness Partnership (PPP), an expert group chaired by Patrick Vallance to advise the G7 presidency held by the government of Prime Minister Boris Johnson.[24]

Positions held

Landray holds the following positions:[25]

  • Professor of Medicine & Epidemiology, Nuffield Department of Population Health, University of Oxford[26]
  • Deputy Director, Big Data Institute, University of Oxford[27]
  • Lead, Big Data & Computing Innovation, MRC Population Health Research Unit[28]
  • Lead, Clinical Informatics & Big Data, NIHR Oxford Biomedical Research Centre[29]
  • Honorary Consultant Physician, Oxford University Hospitals NHS Foundation Trust

References

  1. ^ "Why the UK is ahead of the curve in the global race to find coronavirus treatments - Q&A with Martin Landray". Reaction. 22 April 2020.
  2. ^ "The challenge of saving lives with 'big data'". BBC News. 7 February 2016. Retrieved 16 October 2020.
  3. ^ "ISRCTN - ISRCTN50189673: A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)". www.isrctn.com. Retrieved 2020-09-06.
  4. ^ "Large-scale trial for coronavirus drugs launches in UK". Clinical Trials Arena. 6 April 2020. Retrieved 7 September 2020.
  5. ^ "Managing clinical trials during the pandemic — Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences". www.ndorms.ox.ac.uk. Retrieved 7 September 2020.
  6. ^ "Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 | University of Oxford". www.ox.ac.uk. Retrieved 2020-09-06.
  7. ^ "Prime Minister's statement on coronavirus (COVID-19): 16 June 2020". GOV.UK. Retrieved 2020-09-06.
  8. ^ Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. (July 2020). "Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report". The New England Journal of Medicine. 0. doi:10.1056/NEJMoa2021436. PMC 7383595. PMID 32678530.
  9. ^ "RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial". PMID 33933206. {{cite journal}}: Cite journal requires |journal= (help)
  10. ^ Group, The RECOVERY Collaborative (8 October 2020). "Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19". New England Journal of Medicine. 383 (21): 2030–2040. doi:10.1056/NEJMoa2022926. PMC 7556338. PMID 33031652. Retrieved 16 October 2020. {{cite journal}}: |last1= has generic name (help)
  11. ^ Horby, Peter W.; Mafham, Marion; Bell, Jennifer L.; Linsell, Louise; Staplin, Natalie; Emberson, Jonathan; Palfreeman, Adrian; Raw, Jason; Elmahi, Einas; Prudon, Benjamin; Green, Christopher; Carley, Simon; Chadwick, David; Davies, Matthew; Wise, Matthew P.; Baillie, J. Kenneth; Chappell, Lucy C.; Faust, Saul N.; Jaki, Thomas; Jefferey, Katie; Lim, Wei Shen; Montgomery, Alan; Rowan, Kathryn; Juszczak, Edmund; Haynes, Richard; Landray, Martin J. (5 October 2020). "Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial". The Lancet. 0 (10259): 1345–1352. doi:10.1016/S0140-6736(20)32013-4. ISSN 0140-6736. PMC 7535623. PMID 33031764. Retrieved 16 October 2020.
  12. ^ "Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial". PMID 33545096. {{cite journal}}: Cite journal requires |journal= (help)
  13. ^ . doi:10.1101/2021.03.09.21252736. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)
  14. ^ "Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial". doi:10.1101/2021.03.09.21252736. {{cite journal}}: Cite journal requires |journal= (help)
  15. ^ [1]
  16. ^ "Welcome — RECOVERY Trial". www.recoverytrial.net. Retrieved 16 October 2020.
  17. ^ [2]
  18. ^ [3]
  19. ^ [4]
  20. ^ Entis, Laura (27 January 2016). "Can smartphone drug trials improve medical care?". The Guardian. Retrieved 16 October 2020.
  21. ^ http://eurheartj.oxfordjournals.org/content/ehj/34/41/3161.full.pdf. Retrieved 16 October 2020. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)
  22. ^ https://digital.nhs.uk/services/nhs-digitrials
  23. ^ [5]
  24. ^ New global partnership launched to fight future pandemics Government of the United Kingdom, press release of April 20, 2021.
  25. ^ "Martin Landray — Nuffield Department of Population Health". www.ndph.ox.ac.uk. Retrieved 16 October 2020.
  26. ^ [6]
  27. ^ [7]
  28. ^ [8]
  29. ^ [9]
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Martin_Landray&oldid=1021555704"